ESMO 2022

Dose-dense standard of care is the optimal care

Dose-dense therapy is beneficial for all patients

My highlights of ESMO22

Endocrine response in eBC

Dose dense is better

Reduction of peripheral neuropathy with taxane therapy

Immuntherapy only for low risk patients?

Long-term data on dose density therapy in chemotherapy

QoL and longterm toxicity

Simple and cheap surgical technique may impact survival in early breast cancer

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Consolidating data from prospective studies

Roadmap for the adjuvant setting

DD is the champion!

Datele trialurilor se consolideata

Il vincitore e’ il dose dense!!

Schéma dose-dense bénéfique pour toutes les patientes

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

I miei punti salienti di ESMO22

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Tailoring Adjuvant Therapy

Unmeet needs and my wishes for 2022!

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

How to deal with the negative SERD data?

Status update - adjuvant IO. Are TILs prognostic?

Exciting data, but Phase 3 studies are needed

CDK4/6i could be an option for selected ER+/HER2+ disease

OS not significant, but re-assuring new data

ADC after ADC - is there any orientation?

Sacituzumab govitecan for everybody!

Survival benefit in endocrine sensitive patients

The third in the bunch

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Interim analysis shows promising data on Abema in the 1st Line

VEX has no place in chemotherapy of metastatic breast cancer

New treatment option for heavily pre-treated patients with ER+ MBC

TROPiCS-02 highlights

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

My highlights of ESMO22

Discontinued development

SG is a novel treatment option for HR+/HER2- disease

Update on biomarkers on ADCs of the DAISY trial

More therapy options for patients with HR+, HER2+ disease

Survival benefit from SG in mBC

Another option for heavily pre-treated HR+ advanced breast cancer patients

Negative and yet positive?!

HER2+ and still without chemotherapy

Sopravvivenza globale nello studio MONARCH3

TROPiCS-02 highlights

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

Nouvelles données des analyses expolratoires dans l’étude DAISY

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Survie globale pas encore significative statistiquement mais données rassurantes

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

I miei punti salienti di ESMO22

Sacituzumab Govitecan: Un farmaco per tutte?

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

ADAURA Update - preventing relapse or just delaying it?

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Window for treatment selection

Is OS really needed?

Neoadjuvant strategies for PD-L1 < 1 %

Long term follow-up of ADAURA trial

ADAURA revisited

Osimertinib - curing or delaying relapse?

Osimertinib stays standard adjuvant

Concurrent preoperative IO/CRT in early lung cancer

Pollution and lung cancer - one mechanism revealed

INCREASE - to good to be true?

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Osimertinib bleibt Standard adjuvant

ADAURA revisited

Osimertinib: una cura o ritarda la ripresa di malattia?

Pollution et cancer du poumon - un mécanisme mis en évidence

Langzeitdaten ADAURA

Eine Plattform für "take the winner"-Strategie

Important data on borderline resectable patients

DFS matters!

Sotorasib vs. Docetaxel in mKRAS G12C

Can IO be discontinued?

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

One more brick in the KRAS G12C wall

5 years of chemoimmunotherapy: solid grounded

DESTINY-Lung02 - better than the original?

HER2 - the next actionable mutation in lung cancer?

Emerging IO mono options in the first line

Real-world data on Atezolizumab

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

5-year data on survival under immunotherapy

Pneumonitis and T-DXd

Liquid biopsy monitoring in treatment decisions

New immunotherapy options for pts. ineligible to 1st line platinum therapy

Poseidon and STK11/KEAP

Question about timing and duration of immunotherapy still unanswered

Sotorasib - a new standard of care?

If you don't look, vou don't find - once you found it, you'll treat it!

Sotorasib: sweet and sour results

Atezolizumab better than vinorelbin in reduced performance status

5-year update on 1st line chemoimmunotherapy

Is shorter immunotherapy equally effective and less physically demanding?

Cemiplimab beyond progression?

Induction chemoimmunotherapy in borderline resectability?

Preview on lung cancer highlights

The journey at KRAS G12C continues

New therapy combination after progression on 1L osimertinib

Chemoimmunotherapy - improvement of survival after 5 years

A new step in treatment of KRAS G12C mutant NSCLC

Can we finally treat poor prognostic patients with immunotherapy?

Immunotherapy in unfit population? Perhaps...

Atezo besser als Vino bei PS2-3

Un mattone in piu' nel muro del KRAS G12C

Neue Option der IO-Therapie in der Erstlinie

5 Jahre Chemo-Immuntherapie: starker Effekt

Cemiplimab beyond progression?

Die Reise bei KRAS G12C geht weiter

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

5-Jahresüberleben mit Immuntherapie

Resultados Agridulces de Sotorasib

IO-IO neoadjuvant bei PD-L1 neg.

Pneumonitis und T-DXd

Les études incontournables à l’ESMO 2022

Immunoterapia nella popolazione non fit: forse

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Sotorasib vs. Docetaxel bei mKRAS G12C

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Neue Therapiekombination in der Resistenz nach Osimertinib

Chimio-immunothérapie - amélioration de la survie après 5 ans

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Poseidon und STK11/KEAP

Liquid Biopsy Monitoring zur Therapiesteuerung

Données de vie réelle avec l’atezolizumab

Kann IO pausiert werden?

New strategies in immunotherapy

A positive study! With a question mark?

Novel data and long-term efficacy of chemo-IO in mNSCLC

Heterogenity in the genetic landscape - little progress in molecular alterations

More questions being raised

New combo - triplet therapy for kidney cancer

Place of triplet therapy

No value of IPI/Nivo in the adjuvant setting.

Exciting data for high-risk patients: is this the start of a new era?

Adjuvant Immuntherapy in kidney cancer

Immune-based peri-operative treatment in RCC: What went wrong?

Brief highlights about RCC & urothelial cancer from ESMO22

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

News in terms of adjuvant

Two negative studies question adjuvant approach in RCC

Terapia triple para cancer renales

Inmunoterapia adyuvante en el cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Immunomodulation in combination with checkpointinhibiton

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Shedding light on TKI/Checkpointinhibitor combinations

Therapy combinations in RCC - what is the role of triplet therapy?

EV + pembrolizumab in cisplatin-ineligible patients

EV + Pembro with excellent response rates

Brief highlights about RCC & urothelial cancer from ESMO22

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Promising data, but beware of toxicity

ADCs - a possible therapeutic approach

Biomarker data for better patients selection

Length of hormone therapy after radiation

QoL data from ARASENS triplet therapy study mHRPC

Optimizing cabazitaxel chemotherapy

ADT + ENZA better choice than monotherapy

In older vulnerable - less is more

Radicals - ADT & Radiotherapy

Combination of olaparib leads to promising results

Update on the PROpel study

Further evaluation of PSA correlates

Triplet therapy with darolutamide in prostate cancer

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Genetic testing before PARP therapy is useful

IO + PARP without benefit in the allcomer situation

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

PSA at 8-months as a biomarker

Cabazitaxel better tolerated in elderly men

Uppdatering i PROpel studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Livskvalitetsuppföljning i ARASENS studien

Intimate partner violence in cancer patients

Addition of CPI to Radiochemotherapy in LA-HNSCC?

Novel approach von Biontech towards Cancer – game changing potential?!

New group of substances for rare diseases

TILs - Fashion is the eternal return of the old

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy